Skip to main content
. 2023 Apr 20;24(3):178–184. doi: 10.1002/jgf2.618

TABLE 1.

Demographic characteristics and results of Cox regression analysis in the dataset.

Dataset (n = 175) MOF (n = 28) Cox regression analysis
Univariate Multivariate
p‐Value Risk ratio (95%CI) p‐Value Risk ratio (95%CI)
Female gender 137 (78.3) 23 (82.1) 0.61
Age, year‐old 70.2 (14.6) 74.6 (10.3) 0.10
Follow‐up length, months 52.9 (16.9) 15.8 (12.3) <0.001
Presence of incident MOF 28 (16.0) 28 (100)
BMI, kg/m2 22.2 (4.1) 22.8 (3.1) 0.33
Number of BMI < 18 23 (13.1%) 2 (7.1%) 0.16
Number of BMI > 30 0 (0%) 0 (0%)
BMD in LS, g/cm2 0.734 (0.215) 0.782 (0.121) 0.19
BMD in FN, g/cm2 0.659 (0.152) 0.617 (0.119) 0.14
T‐score in LS −2.21 (1.75) −2.70 (0.98) 0.14
T‐score in FN −2.04 (1.23) −2.39 (0.97) 0.12
CysC/Cr 1.49 (0.29) 1.59 (0.22) <0.05 4.15 (1.09–15.80) 0.39 1.94 (0.42–8.87)
Presence of lifestyle‐related diseases 113 (64.6) 24 (85.7) <0.05 3.60 (1.25–10.40) <0.05 2.92 (1.00–8.54)
Presence of hyper fall‐ability 59 (33.7) 19 (67.9) <0.001 4.90 (2.21–10.86) <0.01 3.93 (1.73–8.95)
Presence of CKD ≥ Grade3a 49 (28.3) 10 (37.0) <0.05 2.57 (1.21–5.43) 0.33 1.46 (0.68–3.17)
Presence of cognitive impairment 12 (6.9) 3 (10.7) 0.77
Presence of rheumatoid arthritis 54 (30.9) 11 (39.3) 0.70
Presence of prevalent MOF 77 (44.0) 21 (75.0) <0.001 5.25 (1.58–17.39) 0.06 2.46 (0.68–6.32)
Antiosteoporotic drug administration 92 (52.6) 19 (67.9) 0.27
Vitamin D supplementation 170 (97.1) 22 (78.6) 0.18
Glucocorticoid steroid administration 12 (6.9) 2 (7.1) 0.89
Presence of polypharmacy 47 (26.9) 10 (35.7) 0.46
Current smoking habitat 7 (4.0) 2 (7.1) 0.29
Alcohol drinking habitat 12 (6.9) 4 (14.3) 0.11

Note: The values are presented as mean (SD) unless indicated otherwise. In the other, number of cases and percentage are presented.

Abbreviations: BMD, bone mineral density; BMI, body mass index; CKD, chronic kidney diseases; CysC/Cr, serum cystatin C‐to‐creatinine ratio; FN, femoral neck; LS, lumbar spine; MOF, major osteoporotic fracture.